INNOVIVA, INC. Net Income (Loss) Attributable to Noncontrolling Interest
INNOVIVA, INC. (INVA) reported Net Income (Loss) Attributable to Noncontrolling Interest of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-26.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToNoncontrollingInterest · last filed 2025-02-26
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-12-31 was $0.00.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-09-30 was $0.00.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for fiscal 2024 was $0.00.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for fiscal 2022 was $6.34M, a 93.84% decline from fiscal 2021.
- INNOVIVA, INC. net income (loss) attributable to noncontrolling interest for fiscal 2021 was $102.98M, a 48.36% increase from fiscal 2020.
| Period end | Net Income (Loss) Attributable to Noncontrolling Interest 3 month | Net Income (Loss) Attributable to Noncontrolling Interest 6 month | Net Income (Loss) Attributable to Noncontrolling Interest 9 month | Net Income (Loss) Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-26 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $0.00 10-K · filed 2025-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 2 quarters · filed 2023-11-01 | $0.00 10-Q · filed 2023-11-01 | $0.00 derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | -$36.18M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | -$36.18M derived: sum of 3 quarters · filed 2025-02-26 | -$15.74M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$36.18M derived: sum of 2 quarters · filed 2025-02-26 | -$15.74M derived: sum of 3 quarters · filed 2025-02-26 | $6.34M 10-K · filed 2025-02-26 |
| 2022-09-30 | -$36.18M 10-Q · filed 2023-11-01 | -$15.74M derived: sum of 2 quarters · filed 2023-11-01 | $6.34M 10-Q · filed 2023-11-01 | $41.65M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $20.43M 10-Q · filed 2023-08-02 | $42.52M 10-Q · filed 2023-08-02 | $77.82M derived: sum of 3 quarters · filed 2024-03-05 | $108.03M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $22.09M 10-Q · filed 2023-05-09 | $57.39M derived: sum of 2 quarters · filed 2024-03-05 | $87.60M derived: sum of 3 quarters · filed 2024-03-05 | $109.50M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $35.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $65.51M derived: sum of 2 quarters · filed 2024-03-05 | $87.41M derived: sum of 3 quarters · filed 2024-03-05 | $102.98M 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $30.21M 10-Q · filed 2022-11-09 | $52.11M derived: sum of 2 quarters · filed 2022-11-09 | $67.68M 10-Q · filed 2022-11-09 | $88.79M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $21.90M 10-Q · filed 2022-07-27 | $37.47M 10-Q · filed 2022-07-27 | $58.58M derived: sum of 3 quarters · filed 2023-02-28 | $71.99M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $15.57M 10-Q · filed 2022-05-05 | $36.69M derived: sum of 2 quarters · filed 2023-02-28 | $50.09M derived: sum of 3 quarters · filed 2023-02-28 | $71.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $21.11M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $34.52M derived: sum of 2 quarters · filed 2023-02-28 | $55.90M derived: sum of 3 quarters · filed 2023-02-28 | $69.41M 10-K · filed 2023-02-28 |
| 2020-09-30 | $13.40M 10-Q · filed 2021-10-27 | $34.78M derived: sum of 2 quarters · filed 2021-10-27 | $48.30M 10-Q · filed 2021-10-27 | $60.21M derived: sum of 4 quarters · filed 2021-10-27 |
| 2020-06-30 | $21.38M 10-Q · filed 2021-07-29 | $34.90M 10-Q · filed 2021-07-29 | $46.81M derived: sum of 3 quarters · filed 2021-07-29 | $54.05M derived: sum of 4 quarters · filed 2021-07-29 |
| 2020-03-31 | $13.52M 10-Q · filed 2021-04-28 | $25.43M derived: sum of 2 quarters · filed 2021-04-28 | $32.67M derived: sum of 3 quarters · filed 2021-04-28 | $40.99M derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $11.91M 10-K · filed 2020-02-19 | $19.16M derived: sum of 2 quarters · filed 2020-10-28 | $27.48M derived: sum of 3 quarters · filed 2020-10-28 | $33.70M 10-K/A · filed 2022-03-17 |
| 2019-09-30 | $7.24M 10-Q · filed 2020-10-28 | $15.56M derived: sum of 2 quarters · filed 2020-10-28 | $21.79M 10-Q · filed 2020-10-28 | $27.25M derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $8.32M 10-Q · filed 2020-07-29 | $14.55M 10-Q · filed 2020-07-29 | $20.00M derived: sum of 3 quarters · filed 2020-07-29 | $23.08M derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | $6.23M 10-Q · filed 2020-04-29 | $11.68M derived: sum of 2 quarters · filed 2020-04-29 | $14.76M derived: sum of 3 quarters · filed 2020-04-29 | $16.75M derived: sum of 4 quarters · filed 2020-04-29 |
| 2018-12-31 | $5.46M 10-K · filed 2020-02-19 | $8.53M derived: sum of 2 quarters · filed 2020-02-19 | $10.52M derived: sum of 3 quarters · filed 2020-02-19 | $11.27M 10-K · filed 2021-02-25 |
| 2018-09-30 | $3.08M 10-K · filed 2020-02-19 | $5.07M derived: sum of 2 quarters · filed 2020-02-19 | $5.82M 10-Q · filed 2019-10-30 | $5.95M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-06-30 | $1.99M 10-K · filed 2020-02-19 | $2.74M 10-Q · filed 2019-07-24 | $2.87M derived: sum of 3 quarters · filed 2020-02-19 | $2.87M derived: sum of 4 quarters · filed 2020-02-19 |
| 2018-03-31 | $749.00K 10-K · filed 2020-02-19 | $878.00K derived: sum of 2 quarters · filed 2020-02-19 | $878.00K derived: sum of 3 quarters · filed 2020-02-19 | $878.00K derived: sum of 4 quarters · filed 2020-02-19 |
| 2017-12-31 | $129.00K 10-K · filed 2019-02-19 | $129.00K derived: sum of 2 quarters · filed 2019-02-19 | $129.00K derived: sum of 3 quarters · filed 2019-02-19 | $129.00K 10-K · filed 2020-02-19 |
| 2017-09-30 | $0.00 10-K · filed 2019-02-19 | $0.00 derived: sum of 2 quarters · filed 2019-02-19 | $0.00 10-Q · filed 2018-10-31 | |
| 2017-06-30 | $0.00 10-K · filed 2019-02-19 | $0.00 10-Q · filed 2018-07-26 | ||
| 2017-03-31 | $0.00 10-K · filed 2019-02-19 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-02-19 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |